pepscience

Bioregulator research · RESEARCH PROFILE

Cortagen

A tetrapeptide explored in neuronal and tissue-response experiments.

1 specification·12 source documents·Source updated Jul 13, 2026

Discuss Cortagen on glp1chat

Join the forum to discuss research with other members.

Visit forum(opens in a new tab)

At a glance

Cortagen is studied for how nerve cells respond to stress or injury. In experimental models, researchers measure changes in gene activity and cell-survival signals; its exact effect depends on the model studied.

Nerve cells react to injury by changing which genes are active and which protective proteins they make. Cortagen is studied for whether it shifts that response in cell and animal models. Researchers can observe a change in survival or injury markers without showing restored memory or movement. This is a proposed way of influencing a cell's stress response, not an established neurological therapy.

Potential benefits & side effects

Interpret each outcome in the context of the study population, formulation and evidence type. Research findings do not establish a personal treatment outcome.

Potential benefits & research findings

The source describes experimental nerve and ischemia-related findings. The origin of each result, particularly animal versus human evidence, is essential context.[1][2][4]

Read the original publications to see the measured endpoints, comparator, duration and uncertainty. Mechanistic plausibility and a favorable experimental result are different from demonstrated clinical benefit.

Side effects & evidence limitations

Interpret the reported adverse effects together with the study population, route and observation period. Small or short studies can miss uncommon and delayed harms. Evidence from a related compound does not establish the safety of Cortagen.

Source-reported adverse effects and cautions

Observations from preclinical and limited clinical literature.

  • Generally well tolerated with no significant adverse effects observed at therapeutic doses in animal studies[5].
  • Occasional mild injection-site reactions (redness/itch) may occur with subcutaneous administration.
  • Sources are available for independent reading. Individual claims and research schedules have not yet undergone an independent clinical review by Pep Science.

    Editorial responsibility
    Pep Science editorial desk
    Last independent review
    Not yet recorded
    Editorial standards & corrections

    SPECIFICATIONS & SOURCE SCHEDULES

    Explore a vial size

    Select the exact formulation. Vial content, target dose and prepared concentration are different measurements.

    Showing 20 mg · 1 source tables

    Source-derived research information. Table phases retain the source’s actual duration; open-ended phases are not converted into a fixed eight-week course. Review the original study before interpreting a schedule.

    Standard Approach (3 mL = 6.67 mg/mL)

    Weeks 1–2Weeks 3–4
    WeekDaily Dose (mcg)Units (per injection) (mL)
    Weeks 1–21000 mcg15 units (0.15 mL)
    Weeks 3–42000 mcg30 units (0.30 mL)

    Frequency: Inject once daily subcutaneously, preferably in the morning[5]. This schedule uses the largest practical dilution (3.0 mL) to keep per-injection units ≥15 for accurate measurement. For doses under ~10 units (<700 mcg), consider using 50-unit or 30-unit insulin syringes for improved readability.

    Additional schedule context & duration

    Concise summary of the once-daily regimen.

    • Goal: Support neural regeneration, cognitive function, and cellular repair mechanisms over time[1][3].
    • Schedule: Daily subcutaneous injections for 4 weeks (extend to 8 weeks if desired).
    • Dose Range: 1000–2000 mcg daily with optional gradual titration.
    • Reconstitution: 3.0 mL per 20 mg vial (6.67 mg/mL) for accurate unit measurements.
    • Storage: Lyophilized frozen; reconstituted refrigerated; avoid repeated freeze–thaw.

    Suggested daily dosing approach based on research.

    • Start: 1000 mcg (1 mg) daily for Weeks 1–2.
    • Target: 2000 mcg (2 mg) daily for Weeks 3–4.
    • Frequency: Once per day (subcutaneous).
    • Cycle Length: 4 weeks standard; optional extension to 8 weeks.
    • Timing: Morning administration preferred; rotate injection sites.

    Read this protocol on Pep Science → · View cited documents ↓

    Preparation

    Preparation and stability depend on the formulation, diluent, container and handling. The source-specific notes below apply to the selected record.
    Reconstitution Steps
    1. Draw 3.0 mL bacteriostatic water with a sterile syringe.
    2. Inject slowly down the vial wall; avoid foaming.
    3. Gently swirl/roll until dissolved (do not shake).
    4. Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.

    Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.

    Storage Instructions

    Proper storage preserves peptide quality[10].

    • Lyophilized: Store at −20 °C (−4 °F) for long-term; 2–8 °C (35.6–46.4 °F) acceptable for short-term (weeks to months).
    • Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within 4 weeks and avoid freeze–thaw.
    • Allow vials to reach room temperature before opening to reduce condensation uptake.

    Injection Technique

    General subcutaneous guidance from clinical best-practice resources[8][9].

    • Clean the vial stopper and skin with alcohol; allow to dry.
    • Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue.
    • Do not aspirate for subcutaneous injections; inject slowly and steadily[9].
    • Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy[8].

    Materials & quantity planning

    Source materials checklist · 20 mg

    Plan based on a 4-week daily protocol with gradual titration (1000–2000 mcg/day).

    • Peptide Vials (Cortagen, 20 mg each):

      • 4 weeks ≈ 3 vials (at average 1500 mcg/day = 42 mg total)
      • 8 weeks ≈ 5 vials
    • Insulin Syringes (U-100):

      • Per week: 7 syringes (1/day)
      • 4 weeks: 28 syringes
      • 8 weeks: 56 syringes
    • Bacteriostatic Water (10 mL bottles): Use 3.0 mL per vial for reconstitution.

      • 4 weeks (3 vials): 9 mL → 1 × 10 mL bottle
      • 8 weeks (5 vials): 15 mL → 2 × 10 mL bottles
    • Alcohol Swabs: One for the vial stopper + one for the injection site each day.

      • Per week: 14 swabs (2/day)
      • 4 weeks: 56 swabs → recommend 1 × 100-count box
      • 8 weeks: 112 swabs → recommend 2 × 100-count boxes

    Calculate a phased quantity

    Enter each finite phase from the schedule you are studying. Open-ended phases need an explicit duration. Calculation uses 20 mg per vial and 3 mL per vial.

    Complete each phase to calculate totals.

    Quantity estimates exclude preparation losses and expiry. Follow the formulation’s handling and disposal requirements.

    FOLLOW THE EVIDENCE

    References & further reading

    Original publications and source documents cited across this product’s variants. A listed source is not an independent endorsement of a dosing schedule.

    Continue exploring

    Related topics are not interchangeable compounds or formulations.